Join
|
Contact
Join
|
Contact












Society News

Jan 2026

FSP Bylaws - Announcing Proposed Changes for 2026

The Board of Directors of the FSP have made recommendations for a revision of the current bylaws which will be reviewed and voted on at the next FSP Business Meeting on Saturday February 14, 2026.
Dec 2025

Get to Know Elena Vrotsos, DO

Get to know your fellow FSP members!
Dec 2025

FSP Nominating Committee Recommended Slate for 2026-2028

The FSP Nominating Committee, chaired by Marilyn Bui, MD, PhD, recommends the slate of candidates for Executive Committee and At-Large Member Board positions for the 2026-2028 term.
Nov 2025

Get to Know Charanjeet Singh, MD

Get to know your fellow FSP members!
Oct 2025

Get to Know Francesca Polit, MD

Get to know your fellow FSP members!
Sep 2025

Get to Know Lamees Saeed, MD

Get to know your fellow FSP members!
Aug 2025

Get to Know Ethan Green, MD

Get to know your fellow FSP members!
Jul 2025

Get to Know Jim Lu, MD, PhD

Get to know your fellow FSP members!
Jul 2025

Biomarker Resource Update: U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression

AbbVie (NYSE: ABBV) announced on May 14, 2025 that EMRELIS™ (telisotuzumab vedotin-tllv) has been granted accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression (OE) who have received a prior systemic therapy.
Jun 2025

Get to Know, Esther Yoon, MD FCAP

Get to know your fellow FSP members!

Pages